Additional Relevant Details Evoke Pharma has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $4.5 million in a registered direct offering. The closing of the offering is expected to take place on or about July 25, 2016, subject to the satisfaction of customary closing conditions.In connection with the offering, the Company will issue approximately 1.8 million registered shares of common stock at a purchase price of $2.49375 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase three-quarters of a share of common stock. The warrants have an exercise price of $2.41 per share, will be exercisable immediately, and will expire five and a half years from the initial exercise date.